Tasimelteon | hsa00020 | Citrate cycle (TCA cycle) | 3.41E-02 | 2 | P50213, O14521 | IDH3A, SDHD | More | |
Tasimelteon | hsa00190 | Oxidative phosphorylation | 4.36E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Tasimelteon | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | |
Tasimelteon | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Tasimelteon | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Tasimelteon | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Tasimelteon | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Tasimelteon | hsa00830 | Retinol metabolism | 3.15E-02 | 1 | P00325 | ADH1B | More | |
Tasimelteon | hsa00920 | Sulfur metabolism | 8.89E-03 | 1 | Q16762 | TST | More | |
Tasimelteon | hsa00970 | Aminoacyl-tRNA biosynthesis | 3.78E-02 | 2 | O95363, Q15046 | FARS2, KARS | More | |
Tasimelteon | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Tasimelteon | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Tasimelteon | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | |
Tasimelteon | hsa01230 | Biosynthesis of amino acids | 3.91E-02 | 3 | P51854, Q99707, P50213 | TKTL1, MTR, IDH3A | More | |
Tasimelteon | hsa03013 | RNA transport | 2.99E-02 | 4 | P38919, P37198, P35658, P55884 | EIF4A3, NUP62, NUP214, EIF3B | More | |
Tasimelteon | hsa03020 | RNA polymerase | 2.94E-07 | 4 | P24928, P62487, Q9GZM3, P52435 | POLR2A, POLR2G, POLR2J2, POLR2J | More | |
Tasimelteon | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | |
Tasimelteon | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | |
Tasimelteon | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | |
Tasimelteon | hsa04062 | Chemokine signaling pathway | 9.23E-03 | 10 | P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | |
Tasimelteon | hsa04122 | Sulfur relay system | 8.89E-03 | 1 | Q16762 | TST | More | |
Tasimelteon | hsa04151 | PI3K-Akt signaling pathway | 3.70E-02 | 12 | P42338, P43657, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P30281 | PIK3CB, P2RY5, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, CCND3 | More | |
Tasimelteon | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | |
Tasimelteon | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | |
Tasimelteon | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | |
Tasimelteon | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | |
Tasimelteon | hsa04530 | Tight junction | 3.60E-03 | 5 | P63261, P16989, P56750, Q92974, Q14247 | ACTG1, CSDA, CLDN17, ARHGEF2, CTTN | More | |
Tasimelteon | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Tasimelteon | hsa04614 | Renin-angiotensin system | 3.52E-02 | 1 | P10619 | CTSA | More | |
Tasimelteon | hsa04659 | Th17 cell differentiation | 1.70E-02 | 7 | P19174, P14784, P14778, P84022, Q13485, P08238, P07766 | PLCG1, IL2RB, IL1R1, SMAD3, SMAD4, HSP90AB1, CD3E | More | |
Tasimelteon | hsa04662 | B cell receptor signaling pathway | 3.64E-03 | 6 | P42338, P60033, P13164, P07948, P21854, Q8N149 | PIK3CB, CD81, IFITM1, LYN, CD72, LILRA2 | More | |
Tasimelteon | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | |
Tasimelteon | hsa04721 | Synaptic vesicle cycle | 1.80E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
Tasimelteon | hsa04924 | Renin secretion | 4.38E-02 | 1 | P07550 | ADRB2 | More | |
Tasimelteon | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | |
Tasimelteon | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
Tasimelteon | hsa05016 | Huntington disease | 2.46E-05 | 3 | Q9GZM3, P52435, Q9NYC9 | POLR2J2, POLR2J, DNAH9 | More | |
Tasimelteon | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Tasimelteon | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | |
Tasimelteon | hsa05140 | Leishmaniasis | 4.50E-03 | 5 | P14598, O60603, P25963, P29350, Q15080 | NCF1, TLR2, NFKBIA, PTPN6, NCF4 | More | |
Tasimelteon | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | |
Tasimelteon | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
Tasimelteon | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Tasimelteon | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | |
Tasimelteon | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | |
Tasimelteon | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |